Eculizumab was safe and effective in the management of transplant-associated thrombotic microangiopathy in a heart transplant recipient with concurrent COVID-19 infection

Intern Med J. 2023 Aug;53(8):1506-1508. doi: 10.1111/imj.16178.

Authors

Chi Xu^{1

2}, Vincent Wong^{1

2}, Ariefandi Kurniawan¹, Scott Wilson^{1

3}, Basu Gopal^{1

3}, Paul D Lawton^{1

3

4}

Affiliations

¹ Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia.
² Department of Renal Services, Western Health, Melbourne, Victoria, Australia.
³ Central Clinical School, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, Victoria, Australia.
⁴ Menzies School of Health Research, Darwin, Northwest Territories, Australia.

PMID: 37599228
DOI: 10.1111/imj.16178

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19* / complications
Heart Transplantation* / adverse effects
Humans
Thrombotic Microangiopathies* / drug therapy
Thrombotic Microangiopathies* / etiology

Substances

eculizumab
Antibodies, Monoclonal, Humanized